| Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches H Lund-Palau, AR Turnbull, A Bush, E Bardin, L Cameron, O Soren, ... Expert review of respiratory medicine 10 (6), 685-697, 2016 | 161 | 2016 |
| Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis WD Smith, E Bardin, L Cameron, CL Edmondson, KV Farrant, I Martin, ... FEMS microbiology letters 364 (14), 2017 | 128 | 2017 |
| Antimicrobial peptide novicidin synergizes with rifampin, ceftriaxone, and ceftazidime against antibiotic-resistant Enterobacteriaceae in vitro O Soren, KS Brinch, D Patel, Y Liu, A Liu, A Coates, Y Hu Antimicrobial agents and chemotherapy 59 (10), 6233-6240, 2015 | 52 | 2015 |
| Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa O Soren, A Rineh, DG Silva, Y Cai, RP Howlin, RN Allan, M Feelisch, ... Journal of Antimicrobial Chemotherapy 75 (1), 117-125, 2020 | 40 | 2020 |
| Cephalosporin-NO-donor prodrug PYRRO-C3D shows β-lactam-mediated activity against Streptococcus pneumoniae biofilms RN Allan, MJ Kelso, A Rineh, NR Yepuri, M Feelisch, O Soren, ... Nitric Oxide 65, 43-49, 2017 | 26 | 2017 |
| Nordihydroguaiaretic acid enhances the activities of aminoglycosides against methicillin-sensitive and resistant Staphylococcus aureus in vitro and in vivo E Cunningham-Oakes, O Soren, C Moussa, G Rathor, Y Liu, A Coates, ... Frontiers in microbiology 6, 1195, 2015 | 23 | 2015 |
| Discovery of Cephalosporin-3′-Diazeniumdiolates That Show Dual Antibacterial and Antibiofilm Effects against Pseudomonas aeruginosa Clinical Cystic Fibrosis … A Rineh, O Soren, T McEwan, V Ravikumar, WH Poh, F Azamifar, ... ACS infectious diseases 6 (6), 1460-1479, 2020 | 20 | 2020 |
| Increased rates of genomic mutation in a biofilm co-culture model of Pseudomonas aeruginosa and Staphylococcus aureus CJ Frapwell, RP Howlin, O Soren, BT McDonagh, CM Duignan, RN Allan, ... BioRxiv, 387233, 2018 | 7 | 2018 |
| Investigation into novel nitric oxide based anti-biofilm strategies to target Pseudomonas aeruginosa infection in Cystic Fibrosis O Soren University of Southampton, 2019 | 2 | 2019 |
| 561: Biofilm phenotyping of patients chronically infected with Pseudomonas aeruginosa reveals a novel, putative biomarker for biofilm infection in cystic fibrosis D Power, O Soren, T Garfield, P Skipp, S Faust, G Connett, J Webb Journal of Cystic Fibrosis 20, S265, 2021 | | 2021 |
| Structure and Regulation of EAL Domain Proteins D Bellini, A Hutchin, O Soren, JS Webb, I Tews, MA Walsh Microbial Cyclic Di-Nucleotide Signaling, 27-48, 2020 | | 2020 |
| 89 Novel targeted nitric oxide donor pro-drugs disrupt biofilms formed by clinical Pseudomonas aeruginosa isolates from cystic fibrosis patients O Soren, R Howlin, G Connett, S Faust, M Kelso, J Webb Journal of Cystic Fibrosis 1 (16), S87, 2017 | | 2017 |
| Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Rev Respir Med. 2016; 10 (6): 685–97 H Lund-Palau, AR Turnbull, A Bush, E Bardin, L Cameron, O Soren, ... Epub 2016/05/14. https://doi. org/10.1080/17476348.2016. 1177460. PubMed …, 0 | | |
